Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
- Associated Conditions
- -
- Associated Therapies
- -
First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 110
- Registration Number
- NCT06730373
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Shengli Oilfield Central Hospital, Dongying, Shandong, China
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT06663007
- Locations
- 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06650332
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06642545
- Locations
- 🇨🇳
Cance Hosoltal Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT06561555
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Target Recruit Count
- 20
- Registration Number
- NCT06492317
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-05-13
- Target Recruit Count
- 32
- Registration Number
- NCT06385873
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Target Recruit Count
- 312
- Registration Number
- NCT06278870
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 63
- Registration Number
- NCT06233864
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06210490
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.